{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=17",
    "query": {
      "condition": "Small Cell Lung Cancer and Breast Cancer",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 492,
    "total_pages": 50,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:30:52.742Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00030498",
      "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Primary Hepatocellular Carcinoma",
        "Adult Subependymoma",
        "Advanced Adult Primary Liver Cancer",
        "Advanced Malignant Mesothelioma",
        "Male Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adult Brain Tumor",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Esophageal Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage II Esophageal Cancer",
        "Stage II Pancreatic Cancer",
        "Stage III Esophageal Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Anal Cancer",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2001-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030498"
    },
    {
      "nct_id": "NCT05001347",
      "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Gastrointestinal Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "TJ004309",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "I-Mab Biopharma US Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-02",
      "completion_date": "2023-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001347"
    },
    {
      "nct_id": "NCT06774963",
      "title": "A Phase 1 Study of LNCB74 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Breast Cancer",
        "Endometrial Cancer",
        "Biliary Tract Cancer",
        "Non-Small Cell Lung Cancer",
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LNCB74",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2025-01-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 14,
      "location_summary": "Newport Beach, California • Edgewood, Kentucky • Boston, Massachusetts + 10 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06774963"
    },
    {
      "nct_id": "NCT02015416",
      "title": "A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Non-small Cell Lung Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "IDC-G305",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-11",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015416"
    },
    {
      "nct_id": "NCT06264921",
      "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Metastatic Tumor",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Endometrial Cancer",
        "Endometrial Neoplasms",
        "Endometrial Diseases",
        "Metastatic Endometrial Cancer",
        "Metastatic Endometrial Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Gastric Cancer",
        "Advanced Gastric Carcinoma",
        "Metastatic Gastric Cancer",
        "Metastatic Gastric Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Lung Carcinoma",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-refractory Ovarian Carcinoma",
        "CCNE1 Amplification",
        "Hormone Receptor Negative Breast Carcinoma",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Progesterone-receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKT3447",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2024-02-23",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06264921"
    },
    {
      "nct_id": "NCT06784193",
      "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)",
        "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
        "Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
        "Metastatic Breast Cancer",
        "Fulvestrant",
        "Palazestrant"
      ],
      "interventions": [
        {
          "name": "OP-3136",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palazestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olema Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2024-12-16",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 13,
      "location_summary": "Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784193"
    },
    {
      "nct_id": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PLN-101095",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pliant Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2023-08-30",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 16,
      "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06270706"
    },
    {
      "nct_id": "NCT01495663",
      "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "I-131-CLR1404",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495663"
    },
    {
      "nct_id": "NCT03149549",
      "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "CX-2009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2017-06-01",
      "completion_date": "2020-09-10",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03149549"
    },
    {
      "nct_id": "NCT01060514",
      "title": "Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2010-02",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-10-15T17:30:52.742Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01060514"
    }
  ]
}